Media headlines about Biogen (NASDAQ:BIIB) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biogen earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.1008465631377 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
Shares of Biogen (BIIB) opened at $335.95 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.90 and a current ratio of 2.19. Biogen has a 52 week low of $244.28 and a 52 week high of $348.84. The stock has a market cap of $71,050.00, a P/E ratio of 20.60, a price-to-earnings-growth ratio of 1.94 and a beta of 0.73.
Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the previous year, the firm earned $5.19 earnings per share. Biogen’s revenue for the quarter was up 4.1% on a year-over-year basis. sell-side analysts predict that Biogen will post 22 EPS for the current year.
Several analysts recently commented on the stock. Bank of America raised their price objective on shares of Biogen from $358.00 to $365.00 and gave the company a “buy” rating in a research note on Wednesday, October 18th. Mizuho set a $400.00 price objective on shares of Biogen and gave the company a “buy” rating in a research note on Friday, January 5th. Canaccord Genuity set a $340.00 target price on shares of Biogen and gave the stock a “hold” rating in a research report on Friday, January 5th. BidaskClub upgraded shares of Biogen from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $390.00 target price on shares of Biogen in a research report on Monday, October 23rd. Ten investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Biogen currently has a consensus rating of “Buy” and an average price target of $350.13.
In other news, CEO Michel Vounatsos bought 780 shares of Biogen stock in a transaction dated Friday, December 29th. The shares were acquired at an average cost of $320.55 per share, with a total value of $250,029.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Alexander J. Denner bought 30,000 shares of Biogen stock in a transaction dated Wednesday, November 29th. The shares were purchased at an average cost of $317.36 per share, for a total transaction of $9,520,800.00. Following the completion of the transaction, the director now owns 10,029 shares of the company’s stock, valued at approximately $3,182,803.44. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 31,560 shares of company stock valued at $10,020,858. 0.25% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Biogen (NASDAQ:BIIB) Share Price” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/14/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-biogen-biib-stock-price.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.